Immunohistochemical overexpression of hypoxia-induced factor 1α associated with slow reduction in 18fluoro-2-deoxy-D-glucose uptake for chemoradiotherapy in patients with pharyngeal cancer-Reference-Cited by-同舟云学术

Immunohistochemical overexpression of hypoxia-induced factor 1α associated with slow reduction in 18fluoro-2-deoxy-D-glucose uptake for chemoradiotherapy in patients with pharyngeal cancer

Published:2016-06-16 Issue:13 Volume:43 Page:2343-2352
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Chen Shang-Wen,Lin Ying-Chun,Chen Rui-Yun,Hsieh Te-Chun,Yen Kuo-Yang,Liang Ji-An,Yang Shih-Neng,Wang Yao-Ching,Chen Ya-Huey,Chow Nan-Haw,Kao Chia-Hung

Funder

Ministry of Health and Welfare

Publisher

Springer Science and Business Media LLC

Subject

Radiology Nuclear Medicine and imaging,General Medicine,Radiology Nuclear Medicine and imaging,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00259-016-3436-z.pdf

Reference31 articles.

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49.

2. Gillison ML, D’Souza G, Westra W, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst. 2008;100:407–20.

3. Ernster JA, Sciotto CG, O’Brien MM, et al. Rising incidence of oropharyngeal cancer and the role of oncogenic human papilloma virus. Laryngoscope. 2007;117:2115–28.

4. Aukema TS, Kappers I, Olmos RA, et al. Is 18F-FDG PET/CT useful for the early prediction of histopathologic response to neoadjuvant erlotinib in patients with non-small cell lung cancer? J Nucl Med. 2010;51:1344–8.

5. Cerci JJ, Pracchia LF, Linardi CC, et al. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. J Nucl Med. 2010;51:1337–43.